Introduction
The availability of clinical genetic testing in the epilepsies has increased dramatically because of rapid progress in identifying the causative mutations (discussed in another article in this issue), 1 as well as advances in laboratory techniques. [2] [3] [4] [5] [6] [7] [8] In addition to trad itional Sanger sequencing, which is used to identify mutations in individual genes linked to epilepsy and related dis orders, clini cians are now presented with an expanded reper toire of testing modalities (Table 1) . Chromo somal microarray analysis (CMA) is now often the first genetic evalu ation con ducted in patients with epilepsy and pro vides information about chromo somal aneuploidies previously detected by high resolution karyotyping, as well as about smaller deletions and duplications.
Epilepsyspecific gene panels have become available to test for sequence vari ants and whole or partial gene deletions and duplications in multiple genes. Currently available panels can simultaneously screen many potentially relevant genes, and do not require the same degree of pretest correla tion of geno type to phenotype as is needed for selection of a singlegene test. These panels also have the advantage of being able to detect intragenic deletions that are below the resolution of CMA and might also be missed by Sanger sequencing (heterozy gous del etion of one or more exons of a gene can not be detected using the Sanger method, because the remaining normal copy of those exons provides a normal sequencing result).
Wholeexome sequencing (WES) is also clinically available, and can provide infor mation about putative pathogenic variantsnot only in genes already known to be related to a specific epilepsy syndrome, but also in genes that might not be expected to harbour mutations, particularly if the epi lepsy phenotype differs from that previously observed to be associated with the variant in question. [9] [10] [11] When applied to a trio (the patient and both biological parents), WES provides an efficient approach to the discov ery of both de novo and inherited mutations in the coding portions of most genes in the human genome. Wholegenome sequen cing (WGS), which is widely performed in the research setting, will probably also shortly be available in the clinic and will provide a means to assay both point muta tions and copy number variations across the whole genome. 12 In this article, we discuss these develop ments and focus on new issues that they bring to light, particularly those related to the benefits and risks of testing and chal lenges for the provision of genetic services (Box 1). Genetic testing in the epilepsies has the potential to revolutionize the care of affected patients, but to ensure services are delivered in the most effective, sensitive, and equitable manner possible, we need to devote attention to the challenges involved and establish mechanisms to address them.
Challenges for interpretation
Each genetic testing modality brings chal lenges related to the interpretation of mol ecular findings in a clinical context. A clearly positive result can provide a defin itive explana tion of the patient's epilepsy. A negative result must be considered within the limits and complexities of the technol ogy and data interpretation, and does not rule out a genetic cause of epilepsy in the in dividual tested.
When interpreting the results of a CMA, in terms of considering the potential patho genicity of a deletion or duplication, fac tors such as the location, size, gene(s) affected, and any relevant association with dis ease cor responding to the individual's phenotype are all very important. For example, in a patient with earlyonset epilepsy, intellectual disabil ity and dysmorphic features, the finding of a deletion or duplication that has previously been reported as patho genic and has been associated with these phenotypic features would be considered a positive result. A neg ative CMA result tells us that a patient does not have a detectable dele tion or duplication, although it is important to keep in mind that this detection technique is becoming more sensitive over time as the technology advances. Often, how ever, individuals have CMA findings that are of undeter mined sig nificance because the detected anomaly has not previously been associated with disease nor specifically classified as benign in data bases such as the Database of Genomic Variants. 13 Such find ings might need to be interpreted in the con text of parental genetic test results. If an unaffected parent carries the same deletion or duplication as a patient with an epilepsy phenotype, the variant is usually judged to be benign, but clinicians must also
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acknowledge the possibility that the variant has incomplete penetrance.
For singlegene or multiplegene (panel) testing, variants in a given gene must be considered carefully in the context of previ ously reported mutations, type of variant, and frequency in the 'background' popu lation (whose sequence data are compiled in a growing number of publicly available data bases, detailed below). Generally, lab oratories will report variants to be patho genic if they have been associated in the literature with the phenotype in question; however, the strength of the published evi dence in favour of pathogenicity varies from in silico predictions of pathogenicity to functional characterization of the muta tion in in vitro or even in vivo models. For a previously unreported variant, the type of variant may aid assessment of its poten tial pathogenicity. For exam ple, a nonsense variant that results in a premature stop codon and protein truncation is more likely to be pathogenic than is a mis sense variant resulting in a single amino acid substitution. In the absence of specific functional studies, however, prediction of the effects of a given variant relies on knowledge of the structure of the gene's protein product and its critical domains, and (for missense variants) conser vation across species of the specific amino acid in question.
New methods to assess a gene's toler ance of variation have been described in the research setting, 9, 14 and several tools to pre dict the functional effects of variants, such as Polyphen2 15 and SIFT, 16 are avail able to laboratories and clinicians. In addition, pub licly available databases such as the 1,000 Genomes Project 17 and the National Heart Lung and Blood Institute Exome Variant Server 18 enable laboratories to evalu ate whether a newly identified variant in a patient with epilepsy has also been seen in popula tions of individuals who are not known to have diseases. How ever, since epilepsy is not a rare disease and the clinical presentation can vary among indi viduals with the same muta tion, even within a family, the finding that a given variant is present at low frequency in these databases does not completely rule out pathogenicity. As with CMA, interpret ation of the potential pathogenicity of a variant identified in singlegene and gene panel testing might require testing of the biological parents of an affected individual.
As WES (and eventually WGS) become more widely used, the same issues will apply.
The current practice of applying WES and WGS to a trio, although costly at the outset, pro vides tremendous efficiency in the analysis of de novo variants. These whole genome approaches will also lead to the iden tification of many additional variants of unknown significance in patients with epi lepsy and the possible identification of novel epilepsyrelated genes. The need for itera tive reevaluation of genetic findings, especially variants of uncertain significance, is increas ingly recognized in the face of this grow ing body of publicly available data. Laborato ries that currently perform clinical gen etic testing for epilepsy are generally willing to reevaluate the potential pathogenicity of vari ants, but this step is currently done on an ad hoc basis and only at the request of treat ing clinicians. To facili tate the interpreta tion and reinterpretation of genetic data, the epi lepsy genetics community might bene fit from the creation of a centralized data base of pathogenic mutations and variants of uncertain significance.
Potential benefits and risks
Several factors need to be considered in evalu ating the potential value of a gen etic test (Box 2). For several epilepsyrelated genes, diagnostic testing has clear implications for treatment or prognosis (Table 2 ). In individ uals suspected to have Dravet syn drome, for example, detection of a patho genic mutation in SCN1A hastens diag nosis, thereby redu cing uncertainty for patients and their fami lies and avoiding expen sive, uncomfortable or inva sive tests (such as repeated imaging, video electroencephalo graphy, muscle biopsy, and lumbar punc ture), as well as pos sibly inappro p riate treatment. 4, 5, 19 A patient might turn out to have a pathogenic muta tion in a gene that was not initially sus pected on the basis of his or her initial present ing p henotype-for example, a mutation that causes a metabolic disease-and the gen etic diagno sis could lead to genespecific treatment, such as pyri doxine therapy for pyridoxine dependent epilepsy.
Even in the absence of implications for treatment, a genetic diagnosis can alert the clinician and patient to screen for other symptoms that are associated with the gene mutation. Importantly, the test results can provide answers to questions about what did or did not cause the disorder, which can bring relief or comfort to patients and caregivers, and might also facilitate procure ment of support from other affected indi viduals or families. A genetic diagnosis can also help with reproductive decisions and, for some families (especially those affected by severe epilepsies associated with develop mental disability), could provide possibili ties for prenatal or preimplantation genetic diagnosis in future pregnancies.
New test modalities have an increased yield of molecular diagnosis, particularly in patients with severe, earlyonset epilep sies. For example, in one study, targeted resequen cing of 265 candidate genes identi fied mutations that were presumed to be diseasecausing in 16 of 33 patients, many of whom had severe epilepsies associated with intellectual disability. 20 Pathogenic muta tions were identified in 10% of patients with infantile epileptic encephalopathies through targeted resequencing of 65 genes 21 and, in approximately 15% of such patients, through WES. 9, 22 However, most epilepsy syndromes are genetically heterogeneous; mutations in different genes cause the same syndrome in different individuals or families, and only a fraction of the potential genetic causes have so far been identified. Consequently, although a positive test result can confirm or suggest that an individual has a specific syndrome, a negative test result might be uninformative. For instance, fewer than 1 in five individuals with autosomal dominant nocturnal frontal lobe epilepsy have a muta tion in any of the genes currently associ ated with that disorder; 4,8 thus, a negative genetic test result does not preclude the clinical diagnosis. Similarly, although use of advanced testing modalities increases the yield of mutation detection substantially, a negative test with these approaches is also uninformative.
Conversely, in syndromes with incom plete penetrance and variable expressivity, a positive test result in an unaffected family member does not necessarily mean that she will develop epilepsy in the future, nor can it predict the specific phenotype if she does. An important example of this problem is genetic epilepsy with febrile seizures plus (GEFS+), in which some family members with a SCN1A mutation remain unaffected, and phenotypes in affected family members vary from simple agelimited febrile seizures to severe epileptic encephalopathies. 4, 5 The risk of epilepsy is increased approxi mately threefold in firstdegree relatives of individuals with epilepsy, 23 and twin studies consistently confirm a genetic component to this increased familial risk. [24] [25] [26] [27] Most people with epilepsy, however, have no affected rela tives. For example, in a population based study conducted by our research group, only around 15% of probands with incident epilepsy had one or more firstdegree rela tive with epilepsy. 23 Most individuals with a family history had just one affected rela tive, and in very few families did the history seem consistent with a Mendelian model of inheritance.
As with many common disorders, inheri tance in the majority of individuals with epilepsy is likely to be complex and multi factorial, with most of the genetic influ ence con tributed by variants that individually have a small or modest effect, and act in con cert with each other and with (as yet unspeci fied) environmental factors. In forms of epilepsy with complex inherit ance, gen etic testing might need to involve analy sis of combinations of riskraising alleles in multiple genes, rather than looking for a causative mutation in a single gene. 28 This Geneticization ■ What will be the effect on public views of epilepsy of the perception that it is a genetic disorder?
Medical education ■ What approaches should be used to ensure that treating clinicians are equipped to recognize when testing should be offered, which tests are most likely to be useful in specific situations, and how to order tests? ■ How can we expand the workforce of genetic counsellors equipped to advise patients and families with epilepsy?
approach, which has yet to be developed, would offer considerable potential, particu larly if it could enable the identification of patient subgroups with different implica tions for treatment or prognosis. Beyond the implications of having a genetic diag nosis for an individual patient, the ability to define cohorts of patients according to geno type could also enable the development of targeted and genotype specific clinical trials.
The potential clinical and personal util ity of genetic testing differs according to whether it is a diagnostic test conducted in individuals who are already known or sus pected to have epilepsy or a predictive test performed in individuals at risk. Whereas many individuals with epilepsy (or their caregivers) are strongly motivated to find the reason why they developed the dis order, how many of their unaffected (but atrisk) relatives would choose to be tested, and what the positive and negative effects of such testing will be, are less clear. A nega tive test result clearly can relieve anxiety and reduce the need for vigilance about pos sible seizure onset. However, a positive test result might also afford benefits, such as enabling individuals to prepare for pos sible seizure onset by alerting their families and physicians, and taking precaution s to prevent accidents. 29 Both diagnostic and predictive genetic testing carry potential risks. Although hav ing a genetic explanation for their epi lepsy is comforting for many individu als, research in other disorders suggests that some affected individuals might have less favourable reactions. 30, 31 A posi tive test result in unaffected relatives, who then face the possibility of future seizure onset, might impair quality of life. Discrimi nation against these individuals in health insurance, life insurance, or employment-or fear thereof-is another possible adverse outcome. 32, 33 In the USA, the Gen etic Information Nondiscrimina tion Act (GINA), enacted in 2008, pro vides pro tection against discrimination in health insur ance but no protection in dis abi lity insur ance, longterm care insurance or life insurance. In addition, GINA does not cover military personnel, certain categ ories of veterans, or individuals cared for by the Indian Health Service. 34 Few studies have specifically addressed genetic testing from the perspective of people with epilepsy. 19, 29, 35, 36 In a qualitative study of risk perception and the perceived effects of genetic testing among research participants, 29 most individuals said they would want genetic testing if it were offered. They cited many potential advantages, including learning what caused epilepsy, being able to make informed reproductive choices, reducing guilt, reliev ing anxiety, and having an improved ability to care and advocate for children at risk. They also expressed concern about potential nega tive effects of genetic testing, including external pressure to modify their repro ductive choices, increased blame and guilt, increased stigma, discrimination in employ ment and insurance, selfimposed limita tions on life goals, and alterations in public conceptions of epilepsy.
Stigma is an important issue that per vades the experience of having epilepsy. [37] [38] [39] [40] [41] [42] The influence of genetic testing on either perceived or actual experiences of stigma or discrimination has not been studied, but research in other stigmatized condi tions provides cause for concern about the conse quences of genetic attributions for epi lepsy, 43, 44 including the possibility that bio logical relatives of people with epilepsy might also experience discrimination 44 and 'associative' 45 or 'courtesy' stigma. 46 Addi tionally, people with epilepsy and their family members have suggested that the increasing perception of epilepsy as a genetic disorder might change the way that the condition is perceived by society at large, with potential positive and nega tive consequences for people with epilepsy as well as their family members. 29 
Provision of genetic services
Challenges for clinicians The landscape of genetic testing for epilepsy is challenging to navigate for many clini cians, which heightens the importance of developing clear guidelines and improving 
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Pyridoxine should be used None medical education in genetics for clinicians working in the field of epilepsy. In addition to understanding the phenotypes in which testing is likely to be useful, and the types of tests available, clini cians must also be famil iar with how to conduct clinical genetic testing, including the need for pretest and posttest genetic counselling, and possibly testing of family members in addition to the patient. Owing to the extreme clinical and genetic heterogeneity of the epilepsies and the rapid pace of genetic discovery, decisions about which test(s) to perform can be com plex. Careful phenotyping-including seiz ure types, age at onset, EEG patterns, and associated comorbidities (such as dys morphic features, intellectual disability, or a movement disorder)-can suggest a syn drome associated with variants in a speci fic gene or set of genes. Targeted test ing of an individual gene or small set of genes (including both sequencing and testing for deletions and duplications within the gene) is likely to be the most appropriate option for such patients. Similarly, CMA should be performed if a largescale del etion or duplication syndrome is suspected. If the pheno type does not suggest a par ticular molecular diagnosis, use of CMA or a panel that includes sequencing and deletion or duplication testing for several epilepsy associated genes might be indicated. This semitargeted approach has the advantage of detecting copy number abnormalities as well as comprehensively assessing known epilepsyrelated genes. When these modali ties fail to result in a clear genetic diagnosis, WES might be indicated.
Another impediment to the provision of genetic testing services is the time (and associated costs) involved. Some physi cians are dissuaded from genetic testing because of the time required for the consent process, obtaining and completing some times cumbersome order forms, followup of results (including variants of uncertain significance, which could in the future be reclassified as either benign or pathogenic, necessitating a system for recontacting patients) and, sometimes, arranging testing of parents or other relatives. As genetic testing continues to be expensive and is not always covered by insurance, physicians also confront the possibility of adding to the patient's financial burden in exchange for knowledge that may not change their clinical management or outcome.
To ensure competence in genetics among physicians in the USA, [47] [48] [49] guidelines have been developed by the National Coali tion for Health Professional Education in Genetics. 50 In addition, a working group convened by the NIH, Centers for Dis ease Control and Prevention, and Health Resources and Services Administration, developed a list of specific genetic knowl edge domains for maternal and child health primary care providers. 51 A similar set of guidelines should be developed for neurologists caring for patients with epi lepsy, particularly in light of the results of a survey of neurologists and psychiatrists in the USA, in which only about onethird of respondents said they were confident about how to order genetic tests. 52, 53 In the same survey, fewer than half of participat ing neurologists reported they had access to a geneticist or genetic counsellor to whom they could refer patients. 53 Few genetic counsellors are familiar with the clini cal and genetic aspects of the epilepsies, and additional training of counsellors is also needed to expand the available work force and ensure access to counselling for disadvantaged populations.
Challenges for patients
Not surprisingly, the concepts surround ing genetic diagnosis, epilepsy inheritance and molecular testing are also challenging for many patients and their families. Many individuals expect that molecular testing will yield a diagnosis, specific prognos tic information, and a specific treatment. In addition, testing may often take place during highly stressful medical situations, such as hospitalization for intractable seiz ures, in the setting of chronic, recurrent or episodic illness that has significantly affected quality of life. Testing of presymp to matic atrisk relatives is also a time of high anxiety. Moreover, when comprehen sive testing approaches are used, positive results might be found in genes that are not expected to be responsible for the patient's epilepsy symptoms, as well as incidental (or secondary) positive findings in genes of relevance to other disorders. In March 2013, the American College of Medical Genetics and Genomics recommended that when WES or WGS is performed for clinical genetic testing, incidental results should be disclosed to patients in rela tion to 57 genes with actionable findings. 54 This recom mendation raised considerable controversy, primarily focused on patients' right to refuse such information and the ethics of disclosing information about adult disorders in children. [55] [56] [57] [58] Cultural, familial and individual vari ations in understanding of epilepsy, [59] [60] [61] [62] heri t ability 63 and risk 64 also need to be addressed. People in families affected by epi lepsy may have 'personal theories of inherit ance' based on their percep tions of shared phy sical or personality traits among family members. 29, 65 Clini cians' fail ure to be aware of these factors can lead to miscommuni cation, conflict and adverse out comes for people with epi lepsy. Conse quently, clini cians need to be prepared both to explain epilepsy, genetic risk and herita bility from a biomedical perspec tive, and to respond sensitively to the ways in which people with epilepsy and their family members un derstand these concepts.
Finally, genetic testing may not be avail able for all segments of the population, particularly because its cost is not always covered by insurance. Though the costs of sequencing are falling rapidly, complex issues persist in relation to laboratory charges, institutional billing and insurance coverage that present barriers to clinical genetic testing for some patients. Advocacy might be needed to ensure equity in avail a bility of genetic testing, particularly in situ ations where clinical utility is poten tially high, as well as in access to treatment following testing.
Genetic counselling
For all the reasons described above, genetic counselling is essential to ensure that affected individuals and family members considering genetic testing for epilepsy are able to make an informed choice. The focus of genetic counselling might differ depending on whether it involves a teen ager or adult with epilepsy, the parents of a young child with epilepsy, or an atrisk family member. The approach to counsel ling should, therefore, be tailored to the individual, but several crucial elements should always be included.
Pretest genetic counselling should include a discussion of the risks, benefits and limi tations of the particular type of test being considered. It is important to emphasize, in realistic terms, the likelihood of a positive test result and the potential influence (often limited or even negligible) that a genetic diagnosis could have on treatment and outcome. Patients (or their parents) need to be aware of the possibility that variants of uncertain significance could be found, and the potential need for followup testing of parents or other family members. Further, it is important that parents understand that genetic testing of young children could reveal epilepsyrelated diagnoses that other wise might not have become apparent for a substantial period of time (such as Lafora progressive myoclonic epilepsy). In relation to WES or WGS, the family should also be informed about the possibility of inciden tal findings unrelated to epilepsy (such as a BRCA1 mutation). Finally, the pretest coun selling session should involve a discussion of the expected turnaround time for obtaining test results, as well as the cost of testing and possible insurance coverage.
Posttest genetic counselling is equally important. Ideally the return of test results should take place during a scheduled, in person followup visit specifically for this purpose. Given that test results might not be available until several months after the initial (pretest) counselling session, patients and their families might not remember the details. Importantly, patients and their family members might not be emotionally prepared to receive genetic test results and could experi ence unanticipated reactions to receiv ing a diagnosis. The parents of very young infants with epilepsy might be extremely distressed to learn that their child has an untreatable genetic condition, some of which are associated with severe intellectual or motor disability. Even parents with a severely disabled child, for whom they have actively sought a genetic diagnosis for many years, could be caught off guard and feel unex pected guilt at having passed on a gene muta tion. Individuals living with epilepsy who themselves have sought a genetic explana tion could find relief in a genetic diagnosis, but might worry about how to communicate the information to other family members, especially those who might also be at risk. Asymptomatic but atrisk family members undergoing predictive testing might experi ence extreme distress on receiving posi tive test results, but even family members who test negative for the gene mutation can feel traumatized and experience survi vor guilt, as observed in other disorders. 66 Genetic counsellors must, therefore, be pre pared to address the guilt, shame and blame that can accompany the receipt of a genetic diagnosis, to provide written resources and information about support organizations that may facili tate contact with other affected families, and to refer individuals to mental health professionals if needed.
The implications of a genetic diagnosis for reproductive decisions are an extremely important concern for people with epilepsy, and criteria are urgently needed for genetic counselling in this context. Evi dence sug gests that many individuals with epilepsy greatly overestimate the risks of epi lepsy in their offspring, and many limit childbear ing because of con cerns about gen etic risk. 35 The potential harms and bene fits of genetic information in this context are a major concern of people in multiplex families. 29 
Future research needs
Research into the genetics of epilepsy is moving very rapidly, and guidelines for the inclusion of new research findings in clini cal testing protocols are urgently needed, based on validity of the findings, their clini cal relevance, and their clinical and per sonal utility for affected individuals. The dis closure of results to participants in epi lepsy genetics research might also be con sidered, and guidelines are needed for these circumstances as well. The development of clinical guidelines should be informed by empirical research involving the intended users of genetic testing-that is, people with epilepsy and their immediate family members, as well as clinicians.
As we have argued previously, 67 research on the ways in which genetic information might alter the experience of living with epi lepsy is urgently needed because of the important psychosocial dimensions, which include stigma, discrimination, reduced rates of marriage and reproduction, and reduced quality of life. 38, 42, [68] [69] [70] [71] [72] [73] [74] We would especially encourage research to address optimal ways to educate clinical care providers in epilepsy genetics, the degree to which affected indi viduals understand the risks and benefits of genetic testing, optimal ways of enabling such individuals to make informed choices, and the positive and negative psychosocial effects on patients and family members of receiving genetic test results. The impact of genetic information is likely to be influ enced by many factors, including the clinical context of epilepsy within a family (severity, age at onset, available treatments), individ ual characteristics (sex, life stage, ethnicity, education), and community context and values (religion, social networks, support, personal preferences).
The future holds promise for the develop ment of new genetic testing approaches that translate into improved care for people with epilepsy, and even methods to prevent the onset of seizures in some atrisk indi viduals. With education and research, we should prepare ourselves for these exciting opportunities, so they can be provided in an optimal manner.
